KabaFusion partners with ‘big name’ in Texas 

LEXINGTON, Mass. – A new joint venture between KabaFusion and Houston-based Memorial Hermann Health System will allow both entities to grow bigger market share, says Dr. Sohail Masood, founder and CEO of KabaFusion. 

Memorial Hermann has 6,700 affiliated physicians and more than 265 care delivery sites throughout the area, providing a platform for KabaFusion as it looks to grow its national footprint. 

“We have a lot of respect for Memorial Hermann,” he said. “Memorial Hermann has been doing home infusion for quite some time very successfully. All we are going to do is help them grow their market bigger market with specialty drugs like IVIG immunoglobulin therapy. They have a captive audience of their own hospital system, but there are other doctors who are not part of the system so our sales and marketing people will focus on those doctors. Memorial Hermann is a big name in the Houston market, and they have relationships in other states.” 

In August 2022, the same year it was acquired by Novo Holdings, KabaFusion nearly doubled its footprint when it acquired several pharmacy locations from Coram, allowing it to enter new markets in Minnesota, Ohio and Tennessee, and expanded its existing reach in California, Florida, New York and Texas.  

Once it’s fully functioning, the company will have about 25 pharmacies nationwide with a similar number of nursing agencies, said Masood. 

“We’re looking at 15 to 20 states where we will have our footprint,” he said. “We’ll be looking at the Carolinas and other places where we’ll take the same model and grow.”  

Masood, who founded KabaFusion in 2010, says he has grown the company 35% year-over-year. His five-year goal is to grow to be a $3 billion company that maintains its patient-centered focus. 

“For me and my team, being patient centric is the most import part,” he said. “That means you have excellent pharmacists and excellent nurses and that’s what we excel in.” 

Masood, who’s been advocating for the home infusion industry since his student days in the 80s, says challenges remain, particularly around reimbursement. 

“We need to keep in mind that somehow, somewhere the payers need to understand home infusion is their cheapest option if they want patients out of the hospital,” he said. “I’m with (growth) in home infusion and alternate infusion centers, insurance companies will look at us more favorably than in the past when they’ve been pennywise and pound foolish.”